David Katz of Sparrow Pharmaceuticals to Receive 2024 Endocrine Society Innovation Award

Sparrow Pharmaceuticals, a company dedicated to improving treatments for endocrine disorders, is set to participate in the Endocrine Society's (ENDO) 2024 Annual Conference from June 1-4 in Boston, MA. At this event, the company's Founder and Chief Scientific Officer, Dr. David A. Katz, will receive the 2024 Laureate Award for Outstanding Innovation.

The Outstanding Innovation Award is given to individuals who have significantly advanced endocrine research or practice. Dr. Katz is being honored for his pioneering research on HSD-1 inhibitors. These inhibitors are emerging as potential therapies for conditions such as Cushing syndrome, autonomous cortisol secretion, and other hypercortisolism forms. They may also benefit patients who require long-term glucocorticoid treatments for conditions like rheumatic diseases. The award ceremony is scheduled for Sunday, June 2nd at 8:00 AM ET.

Expressing his gratitude, Dr. Katz remarked on the recognition from the Endocrine Society, emphasizing the collaborative effort of Sparrow's team and their research partners. "We are dedicated to developing SPI-62 to address the needs of patients suffering from glucocorticoid excess," he stated.

Susan J. Mandel, MD, MPH, Chair of the Laureate Awards Committee at ENDO, highlighted Dr. Katz's foresight and innovation. "David Katz is a visionary entrepreneur and scientist who saw the potential of HSD-1 inhibitors in treating cortisol excess, a debilitating condition. He founded a company to turn this vision into reality and improve patients' lives," she said.

Dr. Katz will also deliver a presentation on HSD-1 inhibition and its potential to mitigate the adverse effects of glucocorticoid excess. His lecture will include interim data from ongoing clinical trials involving patients with polymyalgia rheumatica and ACTH-dependent Cushing’s syndrome.

The details of Dr. Katz’s presentation are as follows:
- Title: HSD11B1 Inhibition Reducing Toxicities of Glucocorticoids
- Presenter: David A. Katz, PhD, Chief Scientific Officer, Sparrow Pharmaceuticals
- Date/Time: Monday, June 3rd, 5:00-5:30 PM ET
- Location: BCEC: 156ABC
- Session: SY55 – Development of Novel Endocrine Therapies by Inhibiting Steroid Biosynthesis

Sparrow Pharmaceuticals was established with the mission to alleviate the adverse effects of steroid use in patients. By leveraging underappreciated scientific insights into glucocorticoid biology, the company aims to develop better treatment options for hypercortisolism and to revolutionize the management of autoimmune and inflammatory conditions. Their lead product, SPI-62, is an oral small molecule designed to target the source of active intracellular glucocorticoids in key tissues.

Dr. Katz’s upcoming presentation and the recognition he is receiving underscore the critical advancements Sparrow Pharmaceuticals is making in the field of endocrinology. The company's innovative approaches and dedication to addressing unmet medical needs highlight the transformative potential of their research and therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!